Capabilities & Highlights

exosomedx a bio-techne brand

Exosome Diagnostics joined the Bio-Techne family in August 2018 with 100 employees globally and growing! Our clinical labs are in Waltham, Massachusetts and Munich Germany. We have in-house expertise in regulatory, bioinformatics and companion diagnostic assay development. We have also completed large, multi-center, international clinical trials. With over 10 years of experience developing liquid biopsies, we have partnerships with the world's leading Bio-Pharmaceutical companies.

The only single step exoRNA + cfDNA co-isolation platform to achieve high sensitivity for rare, low frequency mutations.

We work with all groups to achieve any goal

Biomarker Discovery → Translational / Assay development → Clinical ISO / CLIA – compliant IVD development

cGMP clinical grade exosome isolation exoRNA, exoRNA + cfDNA, exoProtein

Exosome Depletion Non-relevant exosome

Exosome Enrichment Tissue-specific exosome

RNA-Seq Whole transcriptome including coding and non-coding

NGS Panels All mRNAs, 1400 gene pan-cancer, 170 gene medical oncology

Portfolio of Assays EGFR T790M, ALK, ARv7, IDH, & more

Custom Assay Development qPCR, dPCR, mutant enrichment PCR, NGS, protein

Tailored Bioinformatics/AI Tools Biomarker discovery, variant detection

Clinical Tests on the Market (LDT) World's first exosome-based liquid biopsy recommended by NCCN Guidelines for Prostate Cancer Early Detection

Exosomes will empower your projects:
from discovery and pre-clinical projects to clinical trials

- Actively released by all living cells with patient's transcriptome and proteome
- Enables detection of gene rearrangements, splice variants, & RNA editing which are difficult using cfDNA
- Play a role in health and disease
- Not impacted by tumor heterogeneity
- Amenable to frozen storage and highly stable
- More abundant than cfDNA or CTCs
- Provides snapshot of living process

Minimal Inputs
Exosomes are more abundant than cfDNA or CTCs enabling volumes as low as 0.5 mL



Unlock your Biobank!
Exosomes are highly stable, for >10 yrs at -80 °C

Learn more | exosomedx.com • BD@exosomedx.com

EDDE: Specific **E**xosome **D**x **D**epletion or **E**nrichment

EDDE can be tailored for either RNA- or protein-based downstream analyses.

Billions of exosomes are shed into the blood by cells within both healthy and disease/target tissues.
Only a fraction of which will be derived from your target tissue/cell type.



DEPLETION
of Non-relevant Exosomes
Boosts the global signal from the Tumor, Stroma, Immune system.

ENRICHMENT
of the Specific Target You Want
Focus your analysis to cell/tissue type when you have a good protein marker.

Long RNA-Seq: Whole Transcriptome Biomarker Discovery

Interrogate Multiple Biofluids



We can do tissue too!

Detect the Same RNA Diversity as Tissue

Highly Sensitive
with a wide dynamic range



Simple Collection Requirements



EDTA

Cost depends on sample number. Excludes bioinformatic analysis.

Contact **BD@exosomedx.com** to get your estimate!

Custom analytics pipeline with tiered data analysis options

Turn Around Time

We work quickly & efficiently to deliver you high quality results

Service	Process	Turn Around Time*
Long RNA-Seq *or* **OncoSeq Panel**	From sample receipt ➡ analysis	**4–6 weeks**
EDDE Assay Development	Concept ➡ Results	**10–12 weeks**
qPCR/ddPCR Assay Development	Concept ➡ Pre-validation	**6–8 weeks**

* Typical delivery timelines for assays with standard requirements.

Learn more | exosomedx.com • BD@exosomedx.com

bio-techne®
Global bio-techne.com info@bio-techne.com TEL +1 612 379 2956 **North America** TEL 800 343 7475
Europe | Middle East | Africa TEL +44 (0)1235 529449 **China** info.cn@bio-techne.com TEL +86 (21) 52380373